AxoGen, Inc. (NASDAQ:AXGN) – Equities research analysts at Cantor Fitzgerald lifted their FY2017 earnings per share (EPS) estimates for shares of AxoGen in a research report issued on Tuesday. Cantor Fitzgerald analyst T. Steed now expects that the medical equipment provider will earn ($0.28) per share for the year, up from their prior estimate of ($0.30). Cantor Fitzgerald currently has a “Overweight” rating and a $18.00 target price on the stock.

AxoGen (NASDAQ:AXGN) last announced its earnings results on Wednesday, August 2nd. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.02. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The business had revenue of $15.20 million for the quarter, compared to analyst estimates of $14.40 million. During the same period in the previous year, the company earned ($0.09) earnings per share. The company’s revenue for the quarter was up 46.2% compared to the same quarter last year.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at https://www.watchlistnews.com/axogen-inc-to-post-fy2017-earnings-of-0-28-per-share-cantor-fitzgerald-forecasts-axgn/1467690.html.

A number of other research firms have also recently issued reports on AXGN. BidaskClub cut shares of AxoGen from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Leerink Swann assumed coverage on shares of AxoGen in a report on Monday, July 31st. They set an “outperform” rating and a $22.00 price target for the company. ValuEngine upgraded shares of AxoGen from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Wedbush restated an “outperform” rating and set a $14.00 price target (down from $17.00) on shares of AxoGen in a report on Friday, May 19th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $15.90.

Shares of AxoGen (AXGN) opened at 14.70 on Thursday. AxoGen has a 12 month low of $7.65 and a 12 month high of $17.25. The stock’s market capitalization is $488.63 million. The stock’s 50 day moving average price is $15.86 and its 200-day moving average price is $12.85.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. American International Group Inc. raised its position in shares of AxoGen by 7.7% in the first quarter. American International Group Inc. now owns 14,941 shares of the medical equipment provider’s stock worth $156,000 after buying an additional 1,068 shares in the last quarter. SG Americas Securities LLC bought a new position in shares of AxoGen during the first quarter worth approximately $150,000. Millrace Asset Group Inc. raised its position in AxoGen by 4.5% in the first quarter. Millrace Asset Group Inc. now owns 230,000 shares of the medical equipment provider’s stock valued at $2,404,000 after buying an additional 10,000 shares during the period. Trexquant Investment LP acquired a new position in AxoGen during the first quarter valued at about $183,000. Finally, Campbell & CO Investment Adviser LLC raised its position in AxoGen by 3.2% in the first quarter. Campbell & CO Investment Adviser LLC now owns 11,055 shares of the medical equipment provider’s stock valued at $116,000 after buying an additional 341 shares during the period. 64.58% of the stock is owned by institutional investors and hedge funds.

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.